| NEREUS PHARMACEUTICALS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110269969 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF - The present application relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing Salinosporamide A and its analogs that includes forming a compound of formula (VIII). | 11-03-2011 |
| 20110245260 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE - Compounds represented by the following structure (II) are disclosed: | 10-06-2011 |
| 20110172285 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 07-14-2011 |
| 20110160309 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS - Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection. | 06-30-2011 |
| 20110105762 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF - The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing Salinosporamide A and its analogs from a compound of formula (V). | 05-05-2011 |
| 20100168046 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 07-01-2010 |
| 20090298906 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 12-03-2009 |
| 20090285836 | USE OF SALINOSPORAMIDE A TO INHIBIT METASTASIS - The present invention relates to methods and compositions for treating and evaluating metastatic conditions. | 11-19-2009 |
| 20090156469 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF IN TREATING WALDENSTROM'S MACROGLOBULINEMIA - Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I. | 06-18-2009 |
| 20090148445 | METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY - The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN). | 06-11-2009 |
| 20080280968 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 11-13-2008 |
| 20080221183 | ANTI-CANCER AND ANTI-MICROBIAL OXAZOLIDINONES - Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity. | 09-11-2008 |
| 20080221182 | ANTI-CANCER AND ANTI-MICROBIAL OXAZOLIDINONES - Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity. | 09-11-2008 |
